Polycythemia Vera - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 56 pages report, published by Global Markets Direct

Keywords : Polycythemia Vera Therapeutic Products under Development, Key Players in Polycythemia Vera Therapeutics, Polycythemia Vera Pipeline Overview, Polycythemia Vera Pipeline, Polycythemia Vera Pipeline Assessment

Report ThumbnailSeptember-2013
Polycythemia Vera - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Polycythemia Vera - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Polycythemia Vera, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Polycythemia Vera. Polycythemia Vera - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Polycythemia Vera.
- A review of the Polycythemia Vera products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Polycythemia Vera pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Polycythemia Vera.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Polycythemia Vera pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Polycythemia Vera, H2 2013 7
  • Products under Development for Polycythemia Vera - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Late Stage Products, H2 2013 10
  • Mid Clinical Stage Products, H2 2013 11
  • Pre-Clinical Stage Products, H2 2013 12
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Route of Administration, H2 2013 21
  • Assessment by Stage and Route of Administration, H2 2013 22
  • Assessment by Molecule Type, H2 2013 23
  • Assessment by Stage and Molecule Type, H2 2013 24
  • List of Tables
  • Number of Products Under Development for Polycythemia Vera, H2 2013 7
  • Products under Development for Polycythemia Vera - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Comparative Analysis by Late Stage Development, H2 2013 10
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
  • Comparative Analysis by Pre-Clinical Stage Development, H2 2013 12
  • Products under Development by Companies, H2 2013 13
  • Sanofi-Aventis, H2 2013 14
  • Eli Lilly and Company, H2 2013 15
  • Incyte Corporation, H2 2013 16
  • Italfarmaco S.p.A., H2 2013 17
  • PharmaEssentia Corporation, H2 2013 18
  • miRagen Therapeutics, Inc., H2 2013 19
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Stage and Route of Administration, H2 2013 22
  • Assessment by Stage and Molecule Type, H2 2013 24
  • Polycythemia Vera Therapeutics - Drug Profile Updates 37
  • Polycythemia Vera Therapeutics - Discontinued Products 45
  • Polycythemia Vera Therapeutics - Dormant Products 46
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Polycythemia Vera Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Polycythemia Vera 7
  • Polycythemia Vera Therapeutics under Development by Companies 9
  • Late Stage Products 10
  • Comparative Analysis 10
  • Mid Clinical Stage Products 11
  • Comparative Analysis 11
  • Pre-Clinical Stage Products 12
  • Comparative Analysis 12
  • Polycythemia Vera Therapeutics - Products under Development by Companies 13
  • Companies Involved in Polycythemia Vera Therapeutics Development 14
  • Sanofi-Aventis 14
  • Eli Lilly and Company 15
  • Incyte Corporation 16
  • Italfarmaco S.p.A. 17
  • PharmaEssentia Corporation 18
  • miRagen Therapeutics, Inc. 19
  • Polycythemia Vera - Therapeutics Assessment 20
  • Assessment by Monotherapy Products 20
  • Assessment by Route of Administration 21
  • Assessment by Molecule Type 23
  • Drug Profiles 25
  • ruxolitinib - Drug Profile 25
  • Product Description 25
  • Mechanism of Action 25
  • R&D Progress 25
  • peginterferon alfa-2b - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • SAR-302503 - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • MGN-4893 - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • givinostat - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • gandotinib - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • Polycythemia Vera Therapeutics - Drug Profile Updates 37
  • Polycythemia Vera Therapeutics - Discontinued Products 45
  • Polycythemia Vera Therapeutics - Dormant Products 46
  • Polycythemia Vera - Product Development Milestones 47
  • Featured News & Press Releases 47
  • Feb 13, 2013: Novartis's Myelofibrosis Drug Jakavi Turned Down By NICE In Draft Guidance 47
  • Dec 10, 2012: AOP Orphan Pharma Reports Positive Phase II Data Of New Mono-pegylated Interferon Alpha 2b For Treatment Of Polycythemia Vera 48
  • Dec 08, 2010: Incyte Provides Positive Phase II Trial Results Of INCB18424 In Myeloproliferative Neoplasms 49
  • Dec 06, 2010: Incyte Presents Positive Phase II Trial Results Of INCB18424 In Advanced Polycythemia Vera And Essential Thrombocythemia At ASH Annual Meeting 50
  • Oct 18, 2010: S*BIO's SB1518 Receives Orphan Drug Designation From European Commission For Treatment Of Myelofibrosis 51
  • Sep 13, 2010: Incyte Reaches Agreement With FDA On SPA For Phase III Clinical Trial Of INCB18424 In Polycythemia Vera 52
  • May 28, 2009: Incyte Provides Update on Special Protocol Assessment for INCB18424 As A New Treatment for Myelofibrosis 52
  • Jan 06, 2009: Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors from S*BIO 53
  • Jan 05, 2007: TargeGen Selects Jak2 Inhibitor Lead (TG101348) For Clinical Development As A Potential Therapy For Myeloproliferative Diseases Including Polycythemia Vera (PV) 54
  • Appendix 55
  • Methodology 55
  • Coverage 55
  • Secondary Research 55
  • Primary Research 55
  • Expert Panel Validation 55
  • Contact Us 56
  • Disclaimer 56

Please select a license type

Share

Related Products

Global Markets DirectPolycythemia Vera - Pipeline Review, H2 2013Product ThumbnailPolycythemia Vera - Pipeline Review, H2 2013, Industry ReportProduct #: 113334
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved